Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China

医学 随机对照试验 双盲 狭窄 内科学 外科 安慰剂 病理 替代医学
作者
Chengbei Hou,Jing Lan,Yinan Lin,Haiqing Song,Yuan Wang,Wenbo Zhao,Sijie Li,Ran Meng,Junwei Hao,Yuchuan Ding,Marc I. Chimowitz,Marc Fisher,David C. Hess,David S Liebeskind,Derek J. Hausenloy,Jie Huang,Zhenguang Li,Xiujie Han,Jinbo Yang,Jin Zhou,Peimin Chen,Xinchen Zhu,Peilin Hu,Hongbo Pang,Wenwu Chen,Dawei Chen,Guozhong Li,Dingbo Tao,Wei Yue,Zongen Gao,Xunming Ji
出处
期刊:Lancet Neurology [Elsevier]
卷期号:21 (12): 1089-1098 被引量:44
标识
DOI:10.1016/s1474-4422(22)00335-0
摘要

Summary

Background

Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide, and it is associated with a high risk of recurrent stroke with currently recommended treatments. We aimed to evaluate the effect of chronic remote ischaemic conditioning on prevention of ischaemic events in patients with symptomatic ICAS.

Methods

The RICA trial is a multicentre, randomised, double-blind, sham-controlled trial at 84 stroke centres in China. Patients aged 40–80 years with ischaemic stroke or transient ischaemic attack attributable to angiographically verified 50–99% stenosis of a major intracranial artery were randomly assigned (1:1), via an interactive web-based system by computer-generated randomisation code, to either remote ischaemic conditioning or sham remote ischaemic conditioning once daily for 12 months and voluntarily thereafter. All investigators and patients were masked to treatment allocation. The primary efficacy endpoint was the time to first occurrence of non-fatal or fatal ischaemic stroke, with survival analysed by the Kaplan-Meier method. Primary and safety analyses were done in the intention-to-treat population. The RICA trial is registered with ClinicalTrials.gov, number NCT02534545.

Findings

Between Oct 28, 2015, and Feb 28, 2019, 3033 patients were enrolled and randomly assigned to either remote ischaemic conditioning (n=1517; intervention group) or sham remote ischaemic conditioning (n=1516; sham group). Median follow-up was 3·5 years (IQR 2·7–4·4). A non-fatal or fatal ischaemic stroke occurred in 257 (16·9%) patients in the intervention group compared with 288 (19·0%) patients in sham group. There was no difference in the survival distribution for time to first occurrence of non-fatal or fatal ischaemic stroke (hazard ratio 0·87, 95% CI 0·74–1·03; p=0·12). In the intervention group, 79 (5·2%) patients died from any cause, and in the sham group, 84 (5·5%) patients died from any cause (hazard ratio 0·93, 95% CI 0·68–1·27; p=0·65). No intervention-related serious adverse events were observed.

Interpretation

No evidence was found for a difference between remote ischaemic conditioning and sham remote ischaemic conditioning in lowering the risk of ischaemic stroke in patients with symptomatic ICAS. The benefit of remote ischaemic conditioning might have been diluted by poor compliance. Future studies of remote ischaemic conditioning in this population should address challenges in patients' compliance and assess longer term treatment.

Funding

Ministry of Science and Technology China, Beijing Municipal Education Commission, Beijing Municipal Finance Bureau.

Translation

For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zxc完成签到,获得积分10
刚刚
lbt完成签到 ,获得积分10
1秒前
yao完成签到 ,获得积分10
2秒前
2秒前
4秒前
5秒前
5秒前
doudou完成签到 ,获得积分10
5秒前
BCS完成签到,获得积分10
5秒前
领导范儿应助KYN采纳,获得10
5秒前
6秒前
独特的莫言完成签到,获得积分10
8秒前
lin发布了新的文献求助10
9秒前
aero完成签到 ,获得积分10
11秒前
123号完成签到,获得积分10
13秒前
充电宝应助TT采纳,获得10
15秒前
16秒前
16秒前
英姑应助荒野星辰采纳,获得10
18秒前
18秒前
YHY完成签到,获得积分10
20秒前
科研通AI5应助魏伯安采纳,获得10
20秒前
caoyy发布了新的文献求助10
20秒前
21秒前
22秒前
张喻235532完成签到,获得积分10
23秒前
失眠虔纹发布了新的文献求助10
24秒前
香蕉觅云应助糊涂的小伙采纳,获得10
24秒前
24秒前
sutharsons应助科研通管家采纳,获得200
26秒前
打打应助科研通管家采纳,获得10
26秒前
axin应助科研通管家采纳,获得10
26秒前
丘比特应助科研通管家采纳,获得10
26秒前
小蘑菇应助科研通管家采纳,获得10
26秒前
上官若男应助科研通管家采纳,获得10
26秒前
无花果应助科研通管家采纳,获得10
26秒前
26秒前
李健应助科研通管家采纳,获得10
26秒前
CodeCraft应助科研通管家采纳,获得10
26秒前
Ava应助科研通管家采纳,获得10
26秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527998
求助须知:如何正确求助?哪些是违规求助? 3108225
关于积分的说明 9288086
捐赠科研通 2805889
什么是DOI,文献DOI怎么找? 1540195
邀请新用户注册赠送积分活动 716950
科研通“疑难数据库(出版商)”最低求助积分说明 709849